Human albumin is frequently used for infusions and is investigated extensivly in various studies.
The overwhelming concentration of its stabilizers caprylate and acetyltryptophanate results into a decreased binding capacity. The Hepalbin-Adsorbent enables the bed-side reduction of those stabilizers by about 99%.
One Hepalbin™-Adsorbent can remove the stabilizers of 100 ml human albumin solution 20% during infusion significantly.
The purification of more then 100 ml Albumin 20% for infusion or to prepare extracorporeal treatment requires the application of 2 to 6 Hepalbin™-Adsorbents and the use of an infusion pump. The goal is to regenerate free binding sites in order to ligate toxic substances from patients with liver failure.
Human albumin is quantitatively the biggest part of the total protein in the plasma. When infused, the effect is to expand the circulating blood volume.
Its protective function is achieved by binding and releasing of endogenous and exogenous toxins, drugs, fatty acids, vitamins, hormones etc. Thus, albumin takes control of free, hence active substances while simultaneously offering a reservoir.
In liver disease, albumin is administered intravenously as a plasma expander and carrier for toxins or it is used in extracorporeal detoxification as a substitute in plasmapheresis or it is added to the dialysate solution in albumin dialysis in order to increase the removal of albumin bound toxins.
However, as commercial albumin undergoes various steps of virus inactivation and storage, industry is required to add stabilizer molecules to pharmaceutical preparations of albumin.
Unfortunately, this process of stabilization for sterilization and storage has an undesired adverse effect on the theoretical benefit of providing additional binding sites to the patients, as the occupation of binding sites by said stabilizing ligands reduces the availability of binding sites.
In addition, research conducted after the process of albumin stabilization had been established, revealed that tryptophan analogues and caprylate accumulate in liver disease and can precipitate vasodilation and hepatic coma in liver failure.
Native albumin does usually not contain those stabilizers.
The purpose of the Hepalbin™-Adsorbent is to remove caprylate and acetyltryptophanate from albumin when applied to patients with liver disease. This will increase the efficacy of albumin therapy significantly.
The use of albumin in the context of liver disease is established in the following indications:
Albutec GmbH • Schillingallee 68 • 18057 Rostock • Germany Phone: +49-381-12165871 • Fax: +49-381-12165877